Rules 4.7.3 and 4.10.3 ASX Listing Rules Appendix 4G (current at 17/7/2020) Page 1 Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations Name of entity Neurizon Therapeutics Limited ABN/ARBN Financial year ended: 35 094 006 023 30 June...
Appendix 4G and Corporate Governance Statement
Filed with ASX ·
6ix hasn’t read this filing yet.
Neurizon Therapeutics Limited on 6ix
Earlier from Neurizon Therapeutics
- Notification regarding unquoted securities - NUZ
- Elanco representative appointed as Neurizon Board Observer
- Neurizon Completes Initial Drawdown under R&D Facility
- Neurizon Enters Strategic R&D Financing Facility
- Appendix 4C & Quarterly Update
Later from Neurizon Therapeutics
- Appendix 4E and 2026 Annual Report
- Application for quotation of securities - NUZ
- Neurizon Appoints Chief Executive Officer
- NIH funds Expanded Access Program for NUZ-001 in ALS
- Neurizon Announces Partial Redemption of Convertible Notes
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics